Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM)-Reference-Cited by-同舟云学术

Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM)

Published:2020-01-28 Issue: Volume: Page:1-7
ISSN:1018-8665
Container-title:Dermatology
language:en
Short-container-title:Dermatology

Author:

Kornmehl Heather,Callis Duffin Kristina,Salame Nicole,Perez-Chada Lourdes M.,Singh Sanminder,Garg Amit,Gottlieb Alice B.,Latella John,Merola Joseph F.,Armstrong April W.

Publisher

S. Karger AG

Subject

Dermatology

Reference15 articles.

1. Gottlieb AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R, et al.; The International Dermatology Outcome Measures Group. The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. J Am Acad Dermatol. 2015 Feb;72(2):345–8.

2. Callis Duffin K, Gottlieb AB, Merola JF, Latella J, Garg A, Armstrong AW. Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. J Rheumatol. 2017 May;44(5):701–2.

3. Merola JF, Armstrong AW, Saraiya A, Latella J, Garg A, Callis Duffin K, et al. International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: an Update. J Rheumatol. 2016 May;43(5):959–60.

4. Rejas J, Ruiz MA, Pardo A, Soto J. Minimally important difference of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). BMC Med Res Methodol. 2011 Oct;11(1):142.

5. Delestras S, Roustit M, Bedouch P, Minoves M, Dobremez V, Mazet R, et al. Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. PLoS One. 2013;8(2):e56247.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial;Journal of the American Academy of Dermatology;2023-11

2. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials;Therapeutic Advances in Chronic Disease;2023-01

3. Polyaphron Dispersion Technology, A Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application;Dermatology and Therapy;2022-09-01

4. Bimekizumab for the Treatment of Psoriasis;Drugs;2021-10

5. Satisfaction and attitudes toward systemic treatments for psoriasis: A cross‐sectional study;Dermatologic Therapy;2021-03-25